Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Inclusion Criteria:

Must be able to understand and voluntarily sign an informed consent form (ICF).
Must be ≥ 18 years of age at the time of signing the ICF.
Must be able to adhere to the study visit schedule and other protocol requirements.
Patients must have histologically confirmed unresectable NSCLC for which nivolumab is clinically appropriate. Patients must have had one line of prior therapy and have progressed or have discontinued due to toxicity.
Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Immune related Response Criteria (irRC).
Life expectancy > 12 weeks.
Must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
Willingness to have pre treatment and on treatment tumor biopsies.
Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Female patients of childbearing potential must agree to use adequate contraceptive measures until 3 months after the last study drug is taken. Females of childbearing potential must have a negative pregnancy test. It is not known if the antideacetylase activity of this experimental drug may be harmful to the developing fetus or nursing infant.
Male patients should be willing to use barrier contraceptive (ie, condoms) until 3 months after last study drug is taken.

Exclusion Criteria:

Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from giving informed consent.
Any serious concurrent medical conditions, laboratory abnormality, or psychiatric illness that might make the patient nonevaluable, put the patient's safety at risk, or prevent the patient from following the study requirements.
Pregnant or lactating females.
Patients with uncontrolled brain metastases. Existing brain metastases must have been previously treated and currently stable.
Patients who have had chemotherapy within 14 days before entering the study or those who have not recovered from AEs to ≤ Grade 1 due to agents administered more than 14 days earlier.
Previous therapy with histone deacetylase (HDAC) inhibitor and/or anti PD 1, anti PD L1, or anti CTLA4 immunotherapy.

Any of the following laboratory abnormalities:

ANC < 1,500/µL
Platelet count < 100,000/µL
Hematologic growth factors are not allowed at Screening or during the first cycle of treatment
Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)
Creatinine > 1.5 × upper limit of normal (ULN)
AST or ALT > 2.5 × ULN. For patients with liver metastasis AST or ALT > 5 × ULN
Serum total bilirubin > 1.5 mg/dL or > 3 × ULN for patients with hereditary benign hyperbilirubinemia
Corrected QT interval (QTc) using Fridericia's formula (QTcF) value > 480 msec at Screening; family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy at Screening; previous history of drug induced QTc prolongation or the need for treatment with medications known or suspected of producing prolonged QTc intervals on electrocardiogram (ECG).
Congestive heart failure (New York Heart Association Class III or IV), myocardial infarction within 12 months before starting study treatment, or unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris.
Patients with chronic autoimmune disease(s) requiring systemic immunosuppression.
Positive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection.
Patients who received any of the following within the 14 days before initiating study treatment: major surgery, radiation therapy, and/or systemic therapy (standard or an investigational or biological anticancer agent).
Current enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within 14 days of initiating study treatment.
Incidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.